Precision BioSciences Inc (DTIL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.47+1.36%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · DTIL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -71.5% |
| Our one-year growth estimate | diamond | -69.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 1.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
DTIL — litigation filed
Dated 2026-07-27
by reference. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Forward-Looking Statements This C…
Why it matters: It is important to extend the cash runway for stability. Management wants to extend it to 2028.
Watch forManagement says they had a successful financing round. They also plan to cut costs to save cash.
Also watch forManagement says the cash runway is getting shorter. They also report some unexpected costs.
Why it matters: Initial safety data will show how well PBGENE-DMD works in young DMD patients. This is key for future trials.
Supportive ifThe first safety data from the FUNCTION-DMD trial will be out by the end of 2026.
Worry ifNo safety data is released by year-end 2026.
Why it matters: If healthcare sector revenue growth speeds up, it could benefit Precision BioSciences. This may improve investor sentiment.
Supportive ifHealthcare sector revenue growth returns to above 10% year over year.
Worry ifHealthcare sector revenue growth remains below 10% year over year.
Why it matters: Changing the dosing schedule could affect the trial's success and future treatments.
Watch forA new dosing schedule was announced. It will help patients in the ELIMINATE-B trial.
Also watch forNo changes to the dosing schedule or negative feedback from trial results.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$182 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $777 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,854 loss on $10,000 · 58.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on cash management will show if Precision can fund its trials through 2028. This affects investor confidence.
Watch forA press release will confirm that cash runway is enough to support clinical milestones through 2028.
Also watch forA statement may show possible cash shortfalls or funding issues before 2028.
Why it matters: Improving revenue growth would show progress in achieving management's goal of revenue growth. This is crucial for investor confidence.
Supportive ifQ2 revenue exceeds $10.8 million, showing growth from Q1.
Worry ifQ2 revenue is under $10.8 million. This shows a continued decline.
Why it matters: Lawsuit results may change the company's plans for PBGENE-HBV.
Worry ifLitigation ends well for the company. This allows progress on PBGENE-HBV.
Less concerning ifLawsuits can cause delays or limits for PBGENE-HBV.
Why it matters: The terms of the credit agreement could impact the company's cash runway and financial health.
Watch forThe amendment leads to improved cash flow or better loan terms.
Also watch forThe change leads to worse terms or more financial duties.
Why it matters: More data will show how well PBGENE-HBV works to remove cccDNA.
Supportive ifNew clinical data confirms sustained pgRNA loss in patients treated with PBGENE-HBV.
Worry ifClinical data shows no real progress in pgRNA loss or cccDNA removal.
Why it matters: Updates on cash balance will show if the company can fund its clinical trials through 2028. This affects its growth plans.
Supportive ifCash balance remains above $100 million as of the next quarterly report.
Worry ifCash balance falls below $100 million in the next quarterly report.
Why it matters: Extending the credit agreement may give needed cash. This can help the cash runway.
Supportive ifThe company shares better terms or more funding for the credit agreement.
Worry ifThe company faces stricter credit terms or money problems.
Why it matters: Updates will indicate how well PBGENE-HBV is performing in eliminating cccDNA. This is crucial for its success.
Supportive ifUpdates on the PBGENE-HBV trial are provided by year-end 2026.
Worry ifNo updates on PBGENE-HBV trial progress by year-end 2026.
Why it matters: Progress in this trial may mean better gene therapy for Duchenne muscular dystrophy.
Supportive ifMore patients are joining the FUNCTION-DMD trial.
Worry ifStagnation or decrease in patient enrollment for the FUNCTION-DMD trial.